Drug Development Abandonment Stage for Japanese Pharmaceutical Companies
Drug Development Abandonment Stage for Japanese Pharmaceutical Companies
复制标题
日本制药公司的药物开发放弃阶段
DOI：
10.1109/picmet.2016.7806613
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
H. and K. Sumikura
中科院分区：
文献类型：
--
作者：
Saito;H. and K. Sumikura
本文以日本为研究对象，对药物研发被抛弃的阶段进行了实证检验。耗时的新药审批流程涉及多个阶段，确定性较低。基于流水线数据，我们考察了药物开发完全被放弃或“死亡”的阶段。利用日本制药公司的流水线数据，我们调查了药物开发的放弃是否取决于药物的特性。通过对数据的回顾，我们发现药物开发放弃的时间和疾病和技术放弃药物的数量存在差异。
With a focus on Japan, this paper empirically examines the stage in which drug development is abandoned. The time-consuming approval process for new drugs involves many stages and has low certainty. Based on pipeline data, we examine the stage in which drug development is completely abandoned or is “dead.” Using pipeline data on Japanese pharmaceutical companies, we investigate whether the abandonment of drug development depends on the drugs' characteristics. Through a review of the data, we find differences in the timing of drug development abandonment and the number of such abandonment by the disease and technology.